Share “News Summary: Pfizer rheumatoid arthritis...”

News Summary: Pfizer rheumatoid arthritis drug

Associated Press Modified: November 6, 2012 at 5:19 pm •  Published: November 6, 2012

APPROVAL: Pfizer Inc. says the Food and Drug Administration approved its rheumatoid arthritis drug Xeljanz, a twice-per-day pill.

WHO IT'S FOR: Xeljanz is designed to slow the progression of moderate to severe rheumatoid arthritis. It is approved for patients who either cannot take methotrexate, a standard treatment for the disease, or haven't been helped by it. Xeljanz interferes with enzymes that contribute to tissue inflammation.

THE BIG PICTURE: Rheumatoid arthritis is a major area of research for drug companies because it is a chronic condition, meaning patients will likely take the drugs regularly for a long time.


  1. 1
    First hearing on Broken Arrow killings addresses 13-year-old sister's testimony, motion to...
  2. 2
    POPS To Open New Location At Nichols Hills
  3. 3
    Woman arrested in Montana while living under alias to escape warrant in Oklahoma
  4. 4
    Owasso police: DUI suspect claiming to be surgeon threatens 'wait till I get you under my knife'
  5. 5
    Board OKs settlement over principal who hypnotized students
+ show more


× Trending business Article